Novo Nordisk : Le newsflow clinique 2021 centré sur les GLP-1 et le deuxième semestre
>Le marché salue la bonne performance de Rybelsus selon nous - Le titre Novo Nordisk a bien réagi hier à la publication du T4 (+2.7%), pourtant comme nous l’indiquions, la guidance implicite de résultat opérationnel pour 2021 (entre 53.0 et 55.2 MdDKK) est entre 1% et 3% en deçà des attentes du marché (55.9 MdDKK selon le consensus collecté par la société). Nous pensons que ce sont les très bonnes performances commerciales des locomotives de croissances qui ont été sa...Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.